WEBVTT 00:00:00.256 --> 00:00:03.349 A high potassium result can lead to two very different errors. 00:00:03.584 --> 00:00:08.128 Delaying urgent care. Or stopping a beneficial treatment permanently without a review. 00:00:08.576 --> 00:00:10.325 What makes the next decision safer? 00:00:10.495 --> 00:00:12.671 Welcome to HEART RESERVE Clinical Conversations. 00:00:13.012 --> 00:00:16.980 I’m Lisa Zahakos, a physician assistant and founder of HEART RESERVE. 00:00:17.023 --> 00:00:20.756 We will follow Evelyn, Sofia and Margaret through three fictional cases. 00:00:21.161 --> 00:00:26.339 This is education for clinicians. It focuses on recognition, evidence and follow-through, 00:00:26.467 --> 00:00:29.411 and does not replace a local emergency treatment protocol. 00:00:29.667 --> 00:00:32.142 Choose reading or listening for the same activity. 00:00:32.483 --> 00:00:35.264 Begin with the three opening questions on the activity page. 00:00:35.614 --> 00:00:39.240 Then listen to each case, record its decisions, and finish the six 00:00:39.368 --> 00:00:43.379 final questions and brief evaluation. You do not have to complete both 00:00:43.464 --> 00:00:48.265 formats. Case 1. Meet Evelyn. Evelyn is at her kitchen island when 00:00:48.307 --> 00:00:50.526 the patient portal flags a potassium result. 00:00:50.825 --> 00:00:53.001 She feels well and assumes someone will call. 00:00:53.214 --> 00:00:54.980 The clinic sees a hemolysis flag. 00:00:55.167 --> 00:00:58.794 Between those two assumptions, an important result could go unreviewed. 00:00:59.092 --> 00:01:04.703 Initial result. Potassium 5.7 millimoles per liter; specimen reported hemolyzed. 00:01:04.938 --> 00:01:09.441 Background. chronic kidney disease stage three B; stable E G F R 00:01:09.526 --> 00:01:14.198 38 milliliters per minute per one point seven three square meters; hypertension; 00:01:14.476 --> 00:01:20.979 taking losartan. At first contact. No new weakness, palpitations, chest discomfort or 00:01:21.021 --> 00:01:26.355 breathlessness. Your task. Determine urgency, verify the result and close the communication 00:01:26.525 --> 00:01:29.200 loop. Call the patient, not just the laboratory. 00:01:29.443 --> 00:01:33.881 Read the actual value, collection time, specimen comment and prior results. 00:01:34.179 --> 00:01:36.582 A high flag is a starting point for a decision. 00:01:36.894 --> 00:01:39.454 It does not tell you whether Evelyn is at home, has new 00:01:39.497 --> 00:01:42.953 symptoms, has acute kidney injury, or has already taken a medication that 00:01:42.996 --> 00:01:47.251 changes the risk. Contact her and document the clinical context while arranging 00:01:47.336 --> 00:01:50.957 the appropriate next step. Evelyn describes her usual morning. 00:01:51.250 --> 00:01:57.821 Ask specifically about new weakness, palpitations, fainting, chest discomfort, breathlessness, vomiting, poor 00:01:57.907 --> 00:02:03.559 intake and reduced urine output. Review recent illness, medication changes, potassium supplements 00:02:03.687 --> 00:02:08.082 and nonprescription products. Absence of symptoms does not establish a safe potassium 00:02:08.167 --> 00:02:13.616 concentration. A clinically stable first conversation and an emergency presentation require different 00:02:13.786 --> 00:02:17.257 pathways. Decide who owns the alert before ending the call. 00:02:17.528 --> 00:02:20.642 If you request repeat blood work, name the clinician or team who 00:02:20.685 --> 00:02:23.928 will receive and review it, the expected time, the backup if that 00:02:23.970 --> 00:02:27.311 person is unavailable, and what Evelyn should do if symptoms develop. 00:02:27.622 --> 00:02:31.142 A portal message without confirmed follow-through is an incomplete response. 00:02:31.504 --> 00:02:34.406 A hemolysis flag creates a question, not an answer. 00:02:34.790 --> 00:02:38.147 Collection or processing problems can increase measured potassium. 00:02:38.432 --> 00:02:42.357 Ask the laboratory about the specimen and arrange a promptly obtained, properly 00:02:42.485 --> 00:02:45.109 collected repeat using its recommended approach. 00:02:45.429 --> 00:02:48.928 Avoid assuming that the original value is either certainly true or certainly 00:02:49.141 --> 00:02:52.679 false. Review the trend and renal function at the same time. 00:02:52.999 --> 00:02:57.735 Evelyn’s stable presentation makes prompt reassessment feasible, but the repeat test is 00:02:57.778 --> 00:03:00.028 not an excuse for an open-ended delay. 00:03:00.315 --> 00:03:03.921 Local urgency protocols and the clinical presentation govern timing. 00:03:04.198 --> 00:03:09.361 If severe hyperkalemia is suspected or concerning symptoms appear, urgent evaluation and 00:03:09.403 --> 00:03:12.694 treatment must not wait for an ideal confirmatory specimen. 00:03:12.956 --> 00:03:14.919 Pause and consider the first decision. 00:03:15.303 --> 00:03:19.036 Compare the information each option supplies with the information still missing. 00:03:19.569 --> 00:03:23.452 The useful response resolves uncertainty and assigns an action; it does not 00:03:23.495 --> 00:03:26.748 simply relabel the laboratory result. Here is the decision. 00:03:27.004 --> 00:03:30.631 At Evelyn’s first call she is stable, and the potassium of 5.7 00:03:30.759 --> 00:03:34.428 is hemolyzed. Which action best addresses the current uncertainty? 00:03:34.769 --> 00:03:36.954 Pause here if you would like a moment to think it through. 00:03:37.219 --> 00:03:40.889 The best next step in this case is: Arrange prompt properly collected 00:03:41.059 --> 00:03:46.051 repeat testing, assess symptoms, renal function and recent changes, and assign a 00:03:46.094 --> 00:03:47.704 clinician to act on the result. 00:03:48.076 --> 00:03:51.831 Possible sampling artifact needs verification and clinical triage. 00:03:52.215 --> 00:03:56.311 A result-review owner and escalation plan prevent a repeat order from becoming 00:03:56.396 --> 00:04:01.057 a missed abnormal result. The case changes: update the plan immediately. 00:04:01.409 --> 00:04:04.567 Before the repeat result returns, Evelyn calls with new weakness. 00:04:04.823 --> 00:04:08.940 The laboratory reports a nonhemolyzed potassium of 6.6 millimoles per liter. 00:04:09.175 --> 00:04:12.639 Her creatinine is above baseline. This is a new clinical situation. 00:04:12.990 --> 00:04:16.062 The earlier stable phone call does not justify staying on the original 00:04:16.275 --> 00:04:21.054 outpatient pathway. Arrange emergency assessment and monitored treatment through the appropriate local 00:04:21.224 --> 00:04:24.584 route. Do not ask a symptomatic patient to drive herself. 00:04:25.000 --> 00:04:30.589 Communicate the potassium value, specimen reliability, symptoms, kidney trend and current medicines 00:04:30.717 --> 00:04:35.922 to the receiving team. A normal-looking electrocardiogram, if already obtained, does not 00:04:36.007 --> 00:04:41.746 reliably exclude serious hyperkalemia. UK Kidney Association guidance classifies potassium of at 00:04:41.788 --> 00:04:46.963 least 6.5 millimoles per liter as severe and recommends urgent hospital assessment. 00:04:47.231 --> 00:04:52.053 This activity identifies that source explicitly rather than presenting one country’s entire 00:04:52.180 --> 00:04:54.399 protocol as a universal US rule. 00:04:54.740 --> 00:04:59.306 Evelyn’s severe confirmed value and symptoms make the emergency decision clear across 00:04:59.348 --> 00:05:03.901 the case’s context. Separate stabilization from longer-term prevention. 00:05:04.186 --> 00:05:09.306 Emergency teams assess rhythm and instability, protect the myocardium when indicated, shift 00:05:09.391 --> 00:05:14.703 potassium intracellularly and remove potassium according to the presentation and local protocol. 00:05:14.980 --> 00:05:19.560 These actions have different purposes. A treatment that temporarily changes distribution does 00:05:19.645 --> 00:05:23.285 not remove the underlying potassium burden, and recurrence can occur. 00:05:23.553 --> 00:05:28.844 Definitive management may require specialist input, including consideration of dialysis in appropriate 00:05:28.887 --> 00:05:32.866 circumstances. This activity is not an emergency dosing protocol. 00:05:33.133 --> 00:05:37.954 The practical outpatient competency is recognizing when to escalate and communicating enough 00:05:37.997 --> 00:05:43.185 information for timely care. Patiromer and sodium zirconium cyclosilicate are not labeled 00:05:43.227 --> 00:05:45.894 as emergency treatment for life-threatening hyperkalemia. 00:05:46.214 --> 00:05:49.670 Do not substitute a home binder prescription for the monitored response Evelyn 00:05:49.713 --> 00:05:54.340 needs. If acute therapy includes insulin, the receiving team must also manage 00:05:54.511 --> 00:05:57.856 hypoglycemia risk with protocol-directed glucose monitoring. 00:05:58.129 --> 00:06:01.926 Handing off a potassium value without the treatments already given, their times 00:06:02.140 --> 00:06:05.020 and subsequent results can create another safety problem. 00:06:05.425 --> 00:06:07.360 Practice the handoff in one minute. 00:06:07.716 --> 00:06:12.324 A concise case handoff could say: Evelyn, 67, with chronic kidney disease 00:06:12.495 --> 00:06:17.018 and losartan exposure, now has new weakness and a repeat nonhemolyzed potassium 00:06:17.146 --> 00:06:20.223 of 6.6, with kidney function worse than baseline. 00:06:20.442 --> 00:06:24.474 Emergency assessment is being arranged. The previous value was hemolyzed. 00:06:24.709 --> 00:06:29.225 Here are the collection times, recent symptoms, medication list and contact details. 00:06:29.646 --> 00:06:34.510 Notice what is absent: an unsupported diagnosis of permanent angiotensin receptor blocker 00:06:34.596 --> 00:06:37.998 intolerance or a promise that one treatment will solve the problem. 00:06:38.328 --> 00:06:42.210 The immediate handoff should preserve uncertainty where it remains and communicate the 00:06:42.253 --> 00:06:47.458 facts that change urgency. Reflection: imagine the repeat result arrives after your 00:06:47.501 --> 00:06:51.199 shift. Identify the actual person or queue that would receive it in 00:06:51.242 --> 00:06:53.567 your practice. Is the queue monitored? 00:06:53.887 --> 00:06:57.802 Who contacts the patient? What happens if the telephone call is unanswered? 00:06:58.133 --> 00:07:02.016 Think through that workflow before continuing; no written submission is required. 00:07:02.357 --> 00:07:04.832 A small change in the story changes the destination. 00:07:05.088 --> 00:07:09.419 Compare three fictional telephone calls. The first patient feels well, has an 00:07:09.462 --> 00:07:13.088 unexpected hemolyzed result and can obtain a prompt repeat with a clinician 00:07:13.131 --> 00:07:16.288 assigned to review it. The second has the same reported number but 00:07:16.331 --> 00:07:18.797 is vomiting, passing less urine and becoming weak. 00:07:19.087 --> 00:07:22.650 The third has a confirmed severe value but says she feels fine. 00:07:22.970 --> 00:07:25.829 The laboratory number is part of each decision; it is not the 00:07:25.871 --> 00:07:30.074 entire triage assessment. For the first call, the unresolved question is the 00:07:30.116 --> 00:07:32.698 reliability and clinical meaning of the result. 00:07:33.231 --> 00:07:38.081 For the second, acute illness and possible kidney deterioration change the urgency. 00:07:38.366 --> 00:07:42.420 For the third, absence of symptoms does not neutralize a dangerous confirmed 00:07:42.505 --> 00:07:46.558 concentration. The exercise is to identify which facts move the patient out 00:07:46.601 --> 00:07:51.144 of a routine outpatient pathway. Now remove a logistical assumption: the first 00:07:51.230 --> 00:07:55.198 patient cannot get to the laboratory today, the clinic is closing, and 00:07:55.240 --> 00:07:57.389 no one is assigned to the weekend inbox. 00:07:57.746 --> 00:08:01.330 A plan that was reasonable with prompt testing and reliable follow-through may 00:08:01.373 --> 00:08:04.701 no longer be safe. Escalate to a clinician who can arrange an 00:08:04.786 --> 00:08:09.465 appropriate alternative. Access is part of the clinical decision, not an administrative 00:08:09.593 --> 00:08:11.598 detail to solve after the plan is signed. 00:08:11.854 --> 00:08:14.656 A useful note distinguishes facts from inference. 00:08:14.897 --> 00:08:19.496 “Hemolyzed specimen; actual potassium uncertain” records a limitation. 00:08:19.713 --> 00:08:23.600 “No new symptoms reported on direct telephone assessment” records what was asked 00:08:23.814 --> 00:08:26.280 and when. “Probably fine” records neither. 00:08:26.655 --> 00:08:30.281 The goal is a defensible handoff that another clinician can understand without 00:08:30.580 --> 00:08:34.942 reconstructing the entire conversation. What a closed result loop looks like. 00:08:35.251 --> 00:08:39.262 The loop begins when someone acknowledges the abnormal result, continues through patient 00:08:39.432 --> 00:08:43.144 assessment and the chosen action, and ends only when the result and 00:08:43.187 --> 00:08:45.437 plan have reached the person who needs to act. 00:08:45.767 --> 00:08:48.924 A repeat laboratory order is one step inside that loop. 00:08:49.138 --> 00:08:53.103 It is not the endpoint. For Evelyn, the record should connect the 00:08:53.145 --> 00:08:57.199 first result, the reason for confirmation, the new symptoms, the repeat result 00:08:57.455 --> 00:08:59.417 and the change to emergency assessment. 00:08:59.673 --> 00:09:03.253 Preserve the timeline. If another team calls, it should be clear which 00:09:03.381 --> 00:09:05.642 value was hemolyzed and which was reliable. 00:09:05.941 --> 00:09:09.525 If treatment has already been given, communicate what and when rather than 00:09:09.567 --> 00:09:11.861 sending an undifferentiated list of orders. 00:09:12.150 --> 00:09:16.246 After the emergency episode, ask whether the outpatient team received a usable 00:09:16.374 --> 00:09:18.841 medication list and a follow-up responsibility. 00:09:19.175 --> 00:09:21.991 If the hospital note says a medicine was held but the outpatient 00:09:22.162 --> 00:09:25.618 list still says “continue,” the discrepancy needs resolution. 00:09:25.959 --> 00:09:29.380 Do not leave Evelyn to reconcile conflicting instructions by herself. 00:09:29.772 --> 00:09:32.759 Think of the failure you can prevent in your own setting: an 00:09:32.844 --> 00:09:37.495 unmonitored inbox, a result sent to the wrong prescriber, a missed transport 00:09:37.538 --> 00:09:40.055 arrangement or two conflicting medication lists. 00:09:40.311 --> 00:09:43.829 Choose one process to check. You are not being asked to redesign 00:09:43.915 --> 00:09:45.877 the entire system during this activity. 00:09:46.176 --> 00:09:48.501 Close the episode without closing the indication. 00:09:48.821 --> 00:09:52.491 After stabilization, the team will need to distinguish the acute trigger from 00:09:52.533 --> 00:09:56.437 the chronic risk. A temporary medication hold during acute illness is not 00:09:56.565 --> 00:10:00.917 automatically a lifelong prohibition. Record why each medicine was interrupted and what 00:10:00.960 --> 00:10:02.987 must be reassessed before any restart. 00:10:03.222 --> 00:10:05.642 The next case examines that longer-term decision. 00:10:05.972 --> 00:10:11.007 Carry forward both parts of Evelyn’s story: possible artifact still required verification, 00:10:11.263 --> 00:10:14.281 and a later severe result required immediate escalation. 00:10:14.611 --> 00:10:19.390 Neither a reassuring first impression nor a normal-looking electrocardiogram should override the 00:10:19.433 --> 00:10:22.157 updated presentation. Here is the decision. 00:10:22.492 --> 00:10:27.185 Evelyn now has new weakness and a nonhemolyzed potassium of 6.6 millimoles 00:10:27.270 --> 00:10:29.681 per liter. Which action is most appropriate? 00:10:29.788 --> 00:10:31.955 Pause here if you would like a moment to think it through. 00:10:32.245 --> 00:10:35.701 The best next step in this case is: Arrange emergency assessment and 00:10:35.744 --> 00:10:39.371 monitored treatment now; confirmation must not delay urgent care. 00:10:39.797 --> 00:10:44.096 Confirmed severe hyperkalemia with new weakness requires emergency assessment. 00:10:44.340 --> 00:10:48.628 An electrocardiogram without typical changes does not make outpatient delay safe. 00:10:48.863 --> 00:10:53.300 The takeaway. Triage the patient, verify uncertain results and name the result 00:10:53.471 --> 00:10:59.943 owner. Severe or symptomatic hyperkalemia needs emergency assessment; a reassuring electrocardiogram cannot 00:11:00.199 --> 00:11:03.858 exclude danger. Case 2. Meet Sofia. 00:11:04.306 --> 00:11:06.972 Sofia has chronic kidney disease and albuminuria. 00:11:07.250 --> 00:11:10.620 She has worked hard to reduce sodium, switching to a salt substitute 00:11:10.663 --> 00:11:14.711 she thought was healthier. Now two reliable potassium results are elevated, and 00:11:14.754 --> 00:11:19.063 the refill note says “stop losartan.” She asks whether the kidney medicine 00:11:19.106 --> 00:11:24.636 was a mistake. Results. Potassium 5.5 and 5.6 millimoles per liter on 00:11:24.680 --> 00:11:28.839 reliable samples; E G F R 39, near baseline. 00:11:29.287 --> 00:11:34.194 Kidney context. Persistent albuminuria; losartan has an established indication. 00:11:34.536 --> 00:11:39.841 New exposures. Potassium-containing salt substitute and frequent ibuprofen for knee pain. 00:11:40.225 --> 00:11:45.643 Clinical state. Stable, no acute symptoms; timely reassessment is available. 00:11:46.027 --> 00:11:47.848 Start with the indication and the change. 00:11:48.134 --> 00:11:52.485 Sofia’s question deserves a direct answer: an adverse laboratory result does not 00:11:52.571 --> 00:11:54.470 mean the original indication was wrong. 00:11:54.747 --> 00:11:57.769 It means the current balance of benefit and risk needs review. 00:11:58.147 --> 00:12:03.053 Establish why the angiotensin receptor blocker was prescribed, what dose she takes, 00:12:03.352 --> 00:12:07.277 the prior potassium and creatinine trend, and what changed before the abnormal 00:12:07.448 --> 00:12:11.486 results. Review the actual containers rather than relying only on the medication 00:12:11.658 --> 00:12:17.374 list. Ask about over-the-counter pain medicines, supplements, electrolyte powders, herbal products and 00:12:17.418 --> 00:12:20.945 salt substitutes. Sofia has two actionable exposures. 00:12:21.272 --> 00:12:25.966 Arrange a safer pain-management discussion and review the salt substitute’s ingredients. 00:12:26.435 --> 00:12:30.352 A product advertised as lower in sodium may contain potassium chloride. 00:12:30.643 --> 00:12:33.842 The case’s stable kidney function and lack of acute symptoms support a 00:12:33.886 --> 00:12:37.230 structured prompt outpatient response with a reliable safety net. 00:12:37.502 --> 00:12:42.792 If acute illness, rapidly worsening renal function, severe potassium elevation or concerning 00:12:42.920 --> 00:12:47.912 symptoms develop, urgency changes. A chronic-management plan is valid only while its 00:12:47.955 --> 00:12:51.858 assumptions remain true. Do not turn one class warning into a permanent 00:12:51.986 --> 00:12:57.149 stop rule. Kidney Disease Improving Global Outcomes recommends addressing potassium when feasible 00:12:57.406 --> 00:13:02.056 rather than reflexively reducing or stopping an indicated A C E inhibitor 00:13:02.142 --> 00:13:08.312 or angiotensin receptor blocker. It also recognizes limits: symptomatic hypotension or hyperkalemia 00:13:08.440 --> 00:13:13.048 that remains uncontrolled despite treatment may justify reduction or discontinuation. 00:13:13.475 --> 00:13:17.492 The objective is safe, appropriate treatment, not continuation at any cost. 00:13:17.797 --> 00:13:22.256 For routine initiation or dose increase of a renin angiotensin system inhibitor, 00:13:22.448 --> 00:13:27.226 Kidney Disease Improving Global Outcomes suggests blood pressure, creatinine and potassium review 00:13:27.482 --> 00:13:31.476 within two to four weeks, tailored to renal function and potassium. 00:13:31.818 --> 00:13:34.847 That routine interval is not permission to wait weeks after a new 00:13:34.975 --> 00:13:41.127 clinically important abnormal result. Sofia’s active problem needs an earlier individualized reassessment. 00:13:41.391 --> 00:13:46.254 Consider the first case decision. Which option addresses both reversible contributors and 00:13:46.340 --> 00:13:51.076 the indication? Which options either add risk or discard a beneficial therapy 00:13:51.119 --> 00:13:53.625 without enough reasoning? Here is the decision. 00:13:53.911 --> 00:13:58.584 Which initial plan best fits Sofia’s stable presentation and newly identified exposures? 00:13:58.904 --> 00:14:01.223 Pause here if you would like a moment to think it through. 00:14:01.494 --> 00:14:05.931 The best next step in this case is: Address reversible contributors, reassess 00:14:06.060 --> 00:14:11.819 promptly and individualize potassium-lowering measures while reviewing whether the angiotensin receptor blocker 00:14:11.905 --> 00:14:15.787 can safely continue. This applies a cause-directed approach with monitoring. 00:14:16.064 --> 00:14:21.078 Uncontrolled hyperkalemia despite treatment may still require dose reduction or interruption. 00:14:21.398 --> 00:14:24.482 The measured gap: useful, but not causal proof. 00:14:24.794 --> 00:14:30.426 In a retrospective cohort of 5,728 people with chronic kidney disease and 00:14:30.469 --> 00:14:37.451 new hyperkalemia, 13.5 percent discontinued renin angiotensin aldosterone system inhibitors within three 00:14:37.536 --> 00:14:42.770 months. Discontinuation was associated with higher mortality, with an adjusted hazard ratio 00:14:42.942 --> 00:14:49.244 of 1.34 and a 95 percent confidence interval of 1.14 to 1.56. 00:14:49.616 --> 00:14:51.515 The cohort’s mean age was 76. 00:14:51.792 --> 00:14:55.760 These findings describe a defined clinical population, not the future learners in 00:14:55.803 --> 00:14:59.002 this activity. People who stop treatment may be sicker in ways that 00:14:59.045 --> 00:15:03.332 statistical adjustment cannot fully capture. The study therefore does not prove that 00:15:03.375 --> 00:15:06.831 continuing a medicine would prevent an individual patient’s death. 00:15:07.130 --> 00:15:11.439 Its educational value is to make unreviewed discontinuation visible as a process 00:15:11.695 --> 00:15:16.784 worth examining. For Sofia, the actionable question is narrower: have we addressed 00:15:16.869 --> 00:15:21.605 the contributors, specified reassessment, and documented the reason if treatment must be 00:15:21.648 --> 00:15:26.419 interrupted? A statement that stopping is associated with worse outcomes cannot override 00:15:26.547 --> 00:15:30.771 an unsafe potassium result. Build a plan with several options, not one 00:15:30.857 --> 00:15:34.962 product. Dietary counseling should be practical and individualized. 00:15:35.313 --> 00:15:41.030 Review potassium additives and the patient’s usual foods, portion sizes, nutrition, affordability 00:15:41.329 --> 00:15:44.373 and cultural preferences. A renal dietitian can help. 00:15:44.644 --> 00:15:47.844 A blanket instruction to stop all fruits and vegetables is easy to 00:15:47.887 --> 00:15:50.995 give and difficult to justify as a complete strategy. 00:15:51.329 --> 00:15:54.913 The clinician may consider a diuretic when clinically appropriate for blood pressure 00:15:55.169 --> 00:16:00.119 or volume management, correction of relevant metabolic acidosis, or a potassium binder 00:16:00.204 --> 00:16:05.256 for persistent or recurrent hyperkalemia. Each option has its own contraindications and 00:16:05.299 --> 00:16:09.259 monitoring needs. Do not add a diuretic solely to chase a laboratory 00:16:09.345 --> 00:16:13.867 number in a volume-depleted patient, or assume bicarbonate is appropriate without assessing 00:16:13.953 --> 00:16:18.459 the acid-base and volume context. Sofia and the clinician agree on exposure 00:16:18.501 --> 00:16:23.280 changes, a specific repeat laboratory appointment and a same-day result review once 00:16:23.365 --> 00:16:27.333 that test is available. The exact interval and medication decisions belong to 00:16:27.376 --> 00:16:31.581 the treating clinician. She knows which symptoms require urgent care and whom 00:16:31.623 --> 00:16:34.226 to contact if the laboratory appointment cannot happen. 00:16:34.653 --> 00:16:39.602 heart failure with reduced ejection fraction mineralocorticoid receptor antagonist rules are a 00:16:39.645 --> 00:16:44.021 separate decision. Do not carry an A C E inhibitor or angiotensin 00:16:44.063 --> 00:16:49.397 receptor blocker practice point over to every mineralocorticoid receptor antagonist without checking 00:16:49.525 --> 00:16:54.369 the specific indication and guidance. For symptomatic heart failure with reduced ejection 00:16:54.582 --> 00:17:01.239 fraction, the 2022 US heart failure guideline recommends initiating spironolactone or eplerenone 00:17:01.410 --> 00:17:04.524 when E G F R is above 30 and potassium is below 00:17:04.780 --> 00:17:11.030 5.0. If potassium cannot be maintained below 5.5, the guideline recommends discontinuing 00:17:11.200 --> 00:17:15.584 the mineralocorticoid receptor antagonist to avoid life-threatening hyperkalemia. 00:17:15.873 --> 00:17:20.267 These boundaries concern the specified heart failure with reduced ejection fraction steroidal 00:17:20.395 --> 00:17:25.506 mineralocorticoid receptor antagonist context. They are not a universal dosing table for 00:17:25.549 --> 00:17:29.560 finerenone, every phenotype of heart failure, or every kidney indication. 00:17:29.901 --> 00:17:34.092 Use the current product-specific label and indication-specific monitoring instructions. 00:17:34.486 --> 00:17:37.216 A binder does not abolish those safety requirements. 00:17:37.488 --> 00:17:41.495 Sofia is not being asked to start a mineralocorticoid receptor antagonist while 00:17:41.537 --> 00:17:43.860 the current potassium problem is unresolved. 00:17:44.095 --> 00:17:48.698 The distinction matters because “preserve treatment” can otherwise become an overly broad 00:17:48.740 --> 00:17:52.774 instruction to intensify every cardioprotective medicine at once. 00:17:53.109 --> 00:17:55.405 Use a trend without treating it as a guarantee. 00:17:55.653 --> 00:18:01.562 Imagine Sofia’s last three reliable values were 4.7, 5.2 and 5.6. 00:18:01.968 --> 00:18:04.912 The rising pattern helps establish that the current result is not an 00:18:04.954 --> 00:18:08.780 isolated flag, but it does not identify one cause by itself. 00:18:09.234 --> 00:18:14.290 Align the dates with medication changes, illness, supplement use and renal function. 00:18:14.696 --> 00:18:19.060 The time relationship is a clue to investigate, not proof of causation. 00:18:19.413 --> 00:18:22.144 In a different version of the case, the result returns to the 00:18:22.187 --> 00:18:26.384 prior range after the salt substitute and nonprescription exposure are addressed. 00:18:26.741 --> 00:18:30.154 That supports a practical response to the contributors, while leaving a need 00:18:30.197 --> 00:18:35.658 for continued surveillance. In another version, potassium remains elevated and kidney function 00:18:35.871 --> 00:18:40.295 worsens. The clinician must reassess the patient and the treatment balance, rather 00:18:40.423 --> 00:18:42.364 than repeatedly issuing the same advice. 00:18:42.641 --> 00:18:45.073 Ask what the chart would show to a colleague who opens it 00:18:45.116 --> 00:18:49.107 next month. Can that person tell whether the angiotensin receptor blocker is 00:18:49.192 --> 00:18:52.990 active, temporarily held or stopped after a considered review? 00:18:53.416 --> 00:18:56.787 Can the person see why, which result prompted the decision and what 00:18:56.830 --> 00:19:02.307 would trigger reassessment? Medication status is clinical information; ambiguous status can lead 00:19:02.350 --> 00:19:05.251 to duplicate instructions or an indefinite interruption. 00:19:05.635 --> 00:19:08.078 Sofia’s preference also belongs in the discussion. 00:19:08.429 --> 00:19:11.501 She wants kidney protection but worries that every healthy change she makes 00:19:11.629 --> 00:19:16.195 will be criticized. Acknowledge the intention behind the salt substitute, explain the 00:19:16.237 --> 00:19:19.512 specific potassium concern and offer an achievable alternative. 00:19:19.843 --> 00:19:23.043 Invite her to bring packaging or photographs to the next visit, rather 00:19:23.128 --> 00:19:25.435 than expecting her to remember every ingredient. 00:19:25.918 --> 00:19:28.862 Make the counseling actionable without making food the villain. 00:19:29.075 --> 00:19:32.873 A useful dietary conversation begins with what the patient actually eats and 00:19:32.915 --> 00:19:37.101 can afford. Ask who shops and cooks, whether appetite has changed, and 00:19:37.144 --> 00:19:39.981 whether the patient is already restricting several food groups. 00:19:40.258 --> 00:19:42.552 Consider a dietitian referral when available. 00:19:42.927 --> 00:19:45.615 The aim is a plan the patient can carry out while maintaining 00:19:45.743 --> 00:19:50.223 nutrition. Give Sofia one or two specific actions that match the identified 00:19:50.436 --> 00:19:54.942 problem, then check understanding. For example, she can review the salt substitute 00:19:54.984 --> 00:19:58.056 with the clinical team and ask before adding electrolyte products. 00:19:58.398 --> 00:20:01.854 Avoid replacing the whole conversation with an unsorted list of foods to 00:20:01.896 --> 00:20:06.405 avoid. The laboratory follow-up remains necessary even when the dietary discussion goes 00:20:06.490 --> 00:20:08.936 well. The same principle applies to medicines. 00:20:09.121 --> 00:20:13.061 “Avoid anti-inflammatory pain medicines” may be too vague for someone who knows 00:20:13.146 --> 00:20:16.961 only a brand name. Review the actual product and arrange an appropriate 00:20:17.003 --> 00:20:19.585 pain-management alternative with the treating clinician. 00:20:19.905 --> 00:20:23.105 Do not simply remove a coping strategy without addressing the symptom that 00:20:23.147 --> 00:20:26.881 led to it. Before ending, ask Sofia what could prevent the repeat 00:20:27.009 --> 00:20:31.660 test from happening. If the answer is work hours or transportation, resolve 00:20:31.746 --> 00:20:35.147 that constraint or choose a clinically appropriate alternative pathway. 00:20:35.348 --> 00:20:38.377 A plan that relies on an unavailable test has not yet solved 00:20:38.462 --> 00:20:41.534 the safety problem. Work through the counterfactual. 00:20:42.004 --> 00:20:45.766 Suppose Sofia’s repeat potassium remains high despite the agreed measures. 00:20:46.073 --> 00:20:49.827 Recheck what actually happened: did she obtain the test, stop the relevant 00:20:49.913 --> 00:20:53.663 exposure, understand the plan and have access to the prescribed treatment? 00:20:53.915 --> 00:20:58.800 Then reassess clinical stability, renal function and the need for specialist advice. 00:20:59.077 --> 00:21:03.485 Persistent uncontrolled hyperkalemia can warrant medication reduction or interruption. 00:21:03.753 --> 00:21:06.847 Now suppose potassium normalizes after the exposures are addressed. 00:21:07.124 --> 00:21:11.348 Document the result, communicate it, and continue an appropriate monitoring plan. 00:21:11.775 --> 00:21:15.758 Neither branch ends with “no further follow-up needed.” The recurrence risk and 00:21:15.801 --> 00:21:20.665 the medication indication still exist. Reflection: select one phrase you would use 00:21:20.707 --> 00:21:22.841 to explain the plan without blaming Sofia. 00:21:23.097 --> 00:21:26.882 For example: “The lower-sodium product changed your potassium exposure. 00:21:27.127 --> 00:21:30.668 Let’s choose an alternative and check that the plan is working.” The 00:21:30.711 --> 00:21:34.508 case assesses clinical decisions, not a written counseling assignment. 00:21:34.849 --> 00:21:38.759 Here is the decision. A colleague says the discontinuation cohort proves that 00:21:38.802 --> 00:21:41.640 an angiotensin receptor blocker must never be held. 00:21:42.045 --> 00:21:44.946 What is the best response? Pause here if you would like a 00:21:44.989 --> 00:21:47.612 moment to think it through. The best next step in this case 00:21:47.740 --> 00:21:52.775 is: The association supports reassessment of avoidable withdrawal, but does not prove 00:21:52.818 --> 00:21:58.560 causation or override uncontrolled hyperkalemia. Observational evidence can identify a problem worth 00:21:58.603 --> 00:22:03.211 addressing while leaving confounding and individual safety decisions unresolved. 00:22:03.595 --> 00:22:09.170 The takeaway. Review why the medicine is indicated, remove reversible contributors, individualize 00:22:09.298 --> 00:22:14.205 potassium management and reassess. If a hold is needed, document a deliberate 00:22:14.248 --> 00:22:17.220 review and restart decision. Case 3. 00:22:17.562 --> 00:22:21.786 Meet Margaret. Margaret has heart failure with reduced ejection fraction and chronic 00:22:21.871 --> 00:22:26.052 kidney disease. After recurrent hyperkalemia, spironolactone was held. 00:22:26.266 --> 00:22:29.097 Her clinician is considering a binder-supported treatment plan. 00:22:29.241 --> 00:22:31.716 She wants to know whether the new powder will help her live 00:22:31.759 --> 00:22:34.574 longer, and how it fits around her morning medicines. 00:22:34.873 --> 00:22:40.365 Heart and kidney status. left ventricular ejection fraction 32 percent; chronic kidney 00:22:40.408 --> 00:22:44.184 disease stage three B; recent hyperkalemia now stabilized. 00:22:44.461 --> 00:22:50.179 Safety context. Intermittent edema; magnesium near the lower limit of normal; constipation 00:22:50.349 --> 00:22:55.573 history. Daily life. Several oral medicines at breakfast; pharmacy copay and laboratory 00:22:55.659 --> 00:23:01.248 transport are concerns. Your task. Explain the evidence accurately, individualize safety and 00:23:01.291 --> 00:23:05.050 assign follow-through. Begin with the question the patient actually asked. 00:23:05.370 --> 00:23:08.655 Margaret’s question about living longer is different from a question about lowering 00:23:08.783 --> 00:23:12.509 potassium. Explain which outcome each piece of evidence addresses. 00:23:12.822 --> 00:23:16.278 A treatment can improve a laboratory result or make another medicine easier 00:23:16.534 --> 00:23:20.006 to use without having established its own mortality benefit. 00:23:20.277 --> 00:23:26.357 Before considering reintroduction of spironolactone, the clinician reassesses current potassium, kidney function, 00:23:26.634 --> 00:23:30.560 blood pressure, volume status, the cause of the prior episode and the 00:23:30.603 --> 00:23:36.036 indication-specific safety requirements. Her case does not authorize an automatic restart or 00:23:36.079 --> 00:23:39.705 an exact dose. Decisions require a clinician who can review the current 00:23:39.791 --> 00:23:44.173 measurements and arrange follow-up. Ask Margaret to describe the morning routine. 00:23:44.417 --> 00:23:48.257 Which medicines are prescribed, which are taken together, and who helps organize 00:23:48.385 --> 00:23:53.291 them? A theoretically appropriate regimen can fail when its administration schedule, cost 00:23:53.547 --> 00:23:55.692 or testing arrangements cannot be carried out. 00:23:55.958 --> 00:23:59.327 DIAMOND: potassium control and treatment optimization. 00:23:59.709 --> 00:24:05.597 DIAMOND randomized 878 patients with heart failure with reduced ejection fraction and 00:24:05.640 --> 00:24:12.637 current or previous renin angiotensin aldosterone system inhibitor-related hyperkalemia after a patiromer-assisted 00:24:12.680 --> 00:24:18.453 run-in and treatment optimization. Compared with withdrawal to placebo, continuing patiromer improved 00:24:18.538 --> 00:24:24.524 potassium control and reduced recurrent hyperkalemia and mineralocorticoid receptor antagonist dose reductions. 00:24:24.964 --> 00:24:30.382 The selected run-in population matters: participants who reached randomization had already navigated 00:24:30.596 --> 00:24:35.239 an optimization phase. The trial’s primary endpoint was changed from a clinical-outcomes 00:24:35.367 --> 00:24:37.927 endpoint to change in potassium during the study. 00:24:38.225 --> 00:24:42.016 It therefore does not establish a mortality benefit from adding patiromer. 00:24:42.265 --> 00:24:46.446 For Margaret, the relevant discussion is whether a potassium-management strategy can support 00:24:46.660 --> 00:24:49.604 an otherwise appropriate regimen safely and practically. 00:24:49.902 --> 00:24:52.420 It is not a promise that the binder itself has been shown 00:24:52.505 --> 00:24:56.455 to extend her life. Pause and consider what the evidence supports before 00:24:56.626 --> 00:24:59.527 comparing the next study. Here is the decision. 00:24:59.911 --> 00:25:03.282 Margaret asks whether the binder trials prove a survival benefit. 00:25:03.581 --> 00:25:06.635 Which answer is most accurate? Pause here if you would like a 00:25:06.678 --> 00:25:09.451 moment to think it through. The best next step in this case 00:25:09.622 --> 00:25:15.808 is: They support potassium control and selected mineralocorticoid receptor antagonist optimization, but 00:25:15.851 --> 00:25:19.083 do not establish a mortality benefit or a head-to-head ranking. 00:25:19.414 --> 00:25:25.238 Appraise the selected run-in populations, biochemical/treatment endpoints and safety findings separately. 00:25:25.515 --> 00:25:28.097 Neither trial provides a head-to-head binder comparison. 00:25:28.502 --> 00:25:31.626 REALIZE K: read the benefit and the safety finding together. 00:25:31.935 --> 00:25:36.500 REALIZE K randomized 203 selected participants with heart failure with reduced ejection 00:25:36.671 --> 00:25:42.121 fraction after an open-label run-in. The estimated optimal-response proportions were 71 percent 00:25:42.462 --> 00:25:46.786 with sodium zirconium cyclosilicate and 36 percent with placebo. 00:25:47.142 --> 00:25:53.116 Optimal response combined normokalemia, spironolactone of at least 25 milligrams daily and 00:25:53.158 --> 00:25:55.728 no rescue therapy during the specified follow-up. 00:25:56.037 --> 00:26:01.413 The exploratory cardiovascular-death or worsening-heart failure outcome occurred in more participants receiving 00:26:01.584 --> 00:26:05.074 sodium zirconium cyclosilicate: 11 versus 3. 00:26:05.365 --> 00:26:09.205 The trial was not powered to establish clinical-outcome effects, and the imbalance 00:26:09.375 --> 00:26:12.981 is a safety signal rather than proof of a causal mortality effect. 00:26:13.216 --> 00:26:17.513 It must still inform interpretation, particularly in someone with volume concerns. 00:26:17.843 --> 00:26:21.107 Only about one quarter of randomized participants were women. 00:26:21.598 --> 00:26:24.840 Do not claim a women-specific benefit or compare the trial’s effect size 00:26:24.968 --> 00:26:26.910 directly with DIAMOND to rank binders. 00:26:27.187 --> 00:26:29.604 These are different studies, not a head-to-head comparison. 00:26:30.137 --> 00:26:33.081 Translate the labels into a feasible daily schedule. 00:26:33.550 --> 00:26:39.628 Patiromer can cause hypomagnesemia and gastrointestinal adverse effects; monitor magnesium and potassium. 00:26:39.818 --> 00:26:43.189 Its US label generally separates other oral medicines by at least three 00:26:43.274 --> 00:26:47.071 hours, except medicines shown not to have a clinically important interaction. 00:26:47.541 --> 00:26:51.389 Avoid use in severe constipation, obstruction or impaction. 00:26:51.739 --> 00:26:55.276 Margaret’s bowel history and low-normal magnesium deserve review. 00:26:55.614 --> 00:27:01.736 sodium zirconium cyclosilicate contains approximately 400 milligrams sodium per 5 g dose, 00:27:01.971 --> 00:27:05.717 with uncertain absorbed proportion, and carries an edema warning. 00:27:06.006 --> 00:27:09.505 Monitor volume status, especially with heart failure or renal disease. 00:27:09.718 --> 00:27:13.238 Its label generally separates other oral medicines by at least two hours; 00:27:13.558 --> 00:27:16.789 exceptions concern medicines without pH-dependent solubility. 00:27:17.118 --> 00:27:21.001 Review the current label and pharmacist’s interaction assessment rather than inventing a 00:27:21.044 --> 00:27:26.633 universal schedule. Both require preparation as directed, potassium monitoring and dose adjustment 00:27:26.675 --> 00:27:30.766 when needed. Neither replaces emergency care for life-threatening hyperkalemia. 00:27:31.044 --> 00:27:36.334 Access, preferences, cost, preparation burden and the clinician’s assessment all belong in 00:27:36.377 --> 00:27:39.713 the choice. Do not display a brand as the default answer. 00:27:40.062 --> 00:27:42.472 Turn a medication plan into a shared calendar. 00:27:42.750 --> 00:27:47.059 The discharge or clinic plan should list what is continued, held, started 00:27:47.272 --> 00:27:50.163 or being considered, with the reason for each decision. 00:27:50.493 --> 00:27:54.418 Specify the laboratory tests and date, who reviews the result, who covers 00:27:54.589 --> 00:27:58.301 that person, how Margaret receives the decision, and what happens if the 00:27:58.343 --> 00:28:02.236 sample is missed. Use a concrete appointment arranged by the clinical team, 00:28:02.428 --> 00:28:06.012 not an educational generic interval pasted into every case. 00:28:06.566 --> 00:28:10.662 For a held medicine, document the criteria and clinician responsible for reassessing 00:28:10.748 --> 00:28:15.841 restart. The decision should consider the original indication, updated potassium and renal 00:28:15.969 --> 00:28:21.175 function, blood pressure, volume status, interacting medicines and whether the trigger has 00:28:21.217 --> 00:28:25.807 resolved. A hold without a review date can become an unintended permanent 00:28:25.849 --> 00:28:29.900 discontinuation. Ask Margaret to explain the plan back in her own words: 00:28:30.156 --> 00:28:34.636 which medicines go together, which require separation, when she will have blood 00:28:34.722 --> 00:28:36.312 drawn and whom she will call. 00:28:36.621 --> 00:28:40.205 If transport or cost blocks the plan, solve that before treating the 00:28:40.248 --> 00:28:44.088 plan as complete. A pharmacy fill is not evidence that a complex 00:28:44.173 --> 00:28:48.291 schedule was understood. A four-question evidence check at the bedside. 00:28:48.653 --> 00:28:52.556 First ask who was studied. Margaret has heart failure with reduced ejection 00:28:52.770 --> 00:28:56.738 fraction, but a trial that selected participants after a run-in does not 00:28:56.866 --> 00:28:59.331 describe every patient with a new potassium alert. 00:28:59.619 --> 00:29:03.331 People who could not complete optimization may be underrepresented in the randomized 00:29:03.459 --> 00:29:07.683 comparison. That selection limits how confidently the result can be transferred to 00:29:07.726 --> 00:29:10.999 a patient with unstable illness or major practical barriers. 00:29:11.327 --> 00:29:15.509 Second ask what was compared. Continuing a binder versus withdrawing it to 00:29:15.551 --> 00:29:19.263 placebo after run-in is not the same experiment as starting one binder 00:29:19.349 --> 00:29:22.135 versus another in an unselected clinic population. 00:29:22.532 --> 00:29:24.922 The comparator helps explain what the result can answer. 00:29:25.220 --> 00:29:29.039 It cannot support a head-to-head ranking that the investigators did not test. 00:29:29.366 --> 00:29:35.521 Third ask what changed. Potassium concentration, recurrence of hyperkalemia, persistence on a 00:29:35.565 --> 00:29:40.131 mineralocorticoid receptor antagonist and a clinical event are distinct outcomes. 00:29:40.406 --> 00:29:44.351 Do not convert success on one into an unstated claim about another. 00:29:44.741 --> 00:29:48.643 If Margaret asks about longevity, answer that question directly and then explain 00:29:48.859 --> 00:29:51.098 the more limited outcome the trial supports. 00:29:51.413 --> 00:29:54.478 Fourth ask what could go wrong and what remains uncertain. 00:29:54.769 --> 00:29:58.972 A positive efficacy result and a concerning safety finding can coexist. 00:29:59.334 --> 00:30:03.857 REALIZE K’s exploratory heart failure imbalance belongs beside the potassium result in 00:30:03.900 --> 00:30:06.257 the discussion, not in an omitted footnote. 00:30:06.523 --> 00:30:10.406 The appropriate response is a balanced clinical judgment with monitoring, rather than 00:30:10.449 --> 00:30:13.947 either a promise of benefit or a categorical causal claim the trial 00:30:13.990 --> 00:30:17.756 cannot establish. Work through a pharmacy and laboratory handoff. 00:30:18.065 --> 00:30:21.457 Suppose Margaret cannot afford the prescribed binder at the first pharmacy. 00:30:21.862 --> 00:30:25.062 The team should not count the prescription as an implemented plan or 00:30:25.148 --> 00:30:28.019 assume the medicine is being taken while adjusting other treatment. 00:30:28.244 --> 00:30:32.554 Ask the pharmacist and prescribing team to resolve access, consider clinically appropriate 00:30:32.596 --> 00:30:34.815 alternatives and update the monitoring plan. 00:30:35.114 --> 00:30:38.473 Document what Margaret actually has, not only what was ordered. 00:30:39.006 --> 00:30:42.376 Suppose she can obtain it but cannot fit the separation interval around 00:30:42.462 --> 00:30:47.240 breakfast medicines. A pharmacist can review which medicines truly require separation under 00:30:47.326 --> 00:30:50.136 the current label and help construct a feasible schedule. 00:30:50.301 --> 00:30:54.269 The goal is accurate administration, not a complicated calendar that the patient 00:30:54.482 --> 00:30:58.578 quietly abandons. Provide the final agreed schedule in a format she can 00:30:58.621 --> 00:31:02.961 use. Suppose the follow-up potassium result is available, but the ordering clinician 00:31:03.047 --> 00:31:05.898 is away. A backup reviewer should already be identified. 00:31:06.275 --> 00:31:10.328 That person needs the indication, recent medicine changes, prior results and the 00:31:10.371 --> 00:31:15.021 intended decision. A single normal value does not by itself authorize every 00:31:15.150 --> 00:31:19.128 previously held medicine to restart; the clinical context still matters. 00:31:19.395 --> 00:31:23.491 Finally, suppose Margaret reports worsening edema or new breathlessness. 00:31:23.747 --> 00:31:27.843 Reassess the presentation and urgency. Do not dismiss a new symptom because 00:31:27.886 --> 00:31:32.351 the potassium result improved. Her outcome is a whole clinical state, including 00:31:32.479 --> 00:31:37.130 congestion, kidney function, symptoms, treatment burden and the ability to follow the 00:31:37.172 --> 00:31:41.023 plan. Evaluate the care process without claiming patient outcomes. 00:31:41.333 --> 00:31:45.301 In the activity, success means selecting a safe next step and an 00:31:45.386 --> 00:31:50.207 accountable plan. In a later voluntary follow-up, clinicians can report whether they 00:31:50.250 --> 00:31:53.886 adopted a result-owner workflow or documented a restart review. 00:31:54.194 --> 00:31:58.333 Those reports are useful implementation evidence, but they are not verified reductions 00:31:58.589 --> 00:32:03.211 in hospitalization or mortality. Reflection: compare two plans. 00:32:03.481 --> 00:32:07.468 “Repeat blood work and see cardiology” leaves ownership and timing open. 00:32:07.685 --> 00:32:11.401 “The clinic has arranged the laboratory visit; the named clinician reviews it 00:32:11.444 --> 00:32:15.071 that day, a backup covers absence, and Margaret receives a call with 00:32:15.113 --> 00:32:17.792 the medication decision” describes a closed process. 00:32:18.210 --> 00:32:22.007 The latter still needs patient-specific timing and escalation instructions. 00:32:22.562 --> 00:32:27.340 The final six questions revisit recognition, evidence interpretation and follow-through. 00:32:27.724 --> 00:32:30.292 You can read, listen or use the short recap. 00:32:30.556 --> 00:32:34.311 Media playback does not determine completion, and repeating the teaching in another 00:32:34.439 --> 00:32:37.532 format does not create a second activity or extra credit. 00:32:37.852 --> 00:32:41.969 Here is the decision. Which plan best addresses Margaret’s next medication decision 00:32:42.225 --> 00:32:45.894 and the transition home? Pause here if you would like a moment 00:32:46.022 --> 00:32:49.021 to think it through. The best next step in this case is: 00:32:49.298 --> 00:32:54.461 Specify each medication decision and reason, the laboratory date, named result reviewer 00:32:54.546 --> 00:32:59.269 and backup, restart criteria, patient contact and urgent escalation plan. 00:32:59.554 --> 00:33:03.522 A closed handoff turns a temporary safety response into an accountable reassessment 00:33:03.650 --> 00:33:06.573 instead of an indefinite unreviewed discontinuation. 00:33:07.106 --> 00:33:12.363 The takeaway. Keep biochemical efficacy, treatment optimization and clinical outcomes separate. 00:33:12.628 --> 00:33:15.913 Match the binder to safety and daily life, and make every test 00:33:16.084 --> 00:33:21.057 and medication reassessment someone’s responsibility. Bring the three cases back to one 00:33:21.143 --> 00:33:23.788 clinical habit: make the next step explicit. 00:33:24.001 --> 00:33:27.735 Confirm what needs confirmation. Escalate what needs emergency care. 00:33:27.927 --> 00:33:30.995 Review reversible contributors and the reason for each medicine. 00:33:31.161 --> 00:33:34.233 Keep potassium control separate from a claim about survival. 00:33:34.532 --> 00:33:37.348 And give every test and medication review an owner. 00:33:37.689 --> 00:33:40.603 The full references and transcript are available with this episode. 00:33:40.957 --> 00:33:44.370 Return to the activity page to record your decisions, complete the six 00:33:44.499 --> 00:33:47.890 final questions and evaluation, and download your completion record. 00:33:48.210 --> 00:33:50.728 This has been HEART RESERVE Clinical Conversations. 00:33:51.026 --> 00:33:53.578 I’m Lisa Zahakos. Thank you for listening.